EXEL
USDExelixis Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$37.810
Kõrge
$38.900
Madal
$37.582
Maht
2.81M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
10.2B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.62M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for
Guggenheim Downgrades Exelixis to Neutral
Guggenheim analyst Michael W. Schmidt downgrades Exelixis from Buy to Neutral.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after
Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
Morgan Stanley analyst Sean Laaman maintains Exelixis with a Overweight and lowers the price target from $50 to $44.
RBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target
RBC Capital analyst Leonid Timashev reiterates Exelixis with a Sector Perform and maintains $45 price target.
Wells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30
Wells Fargo analyst Derek Archila maintains Exelixis with a Equal-Weight and lowers the price target from $36 to $30.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.